Avid Bioservices Inc (CDMO)

[biopharm]

Lets take a little history and look back at the early studies of Ipilimumab and hmmmm, could it be that Medarex actually had a nice little peek into the Ipilimumab(Yervoy)+PS targeting several years ago and then BAMM.... stomped on by a little buyout by our friendly neighbor BMS. Keep reading though... because it gets a little interesting and lets not forget that it was actually a little "David Sherris" deal from Peregrine + Medarex back in 2009 and only months later--- thats when BMS gulps down Medarex with ... hmmmm, a measly $2.9B 90% premium buyout.

So how does Dr James Allison fit in....and did BMS become concerned. Once Medarex teamed with Dr Allison..?

..After publishing his findings in 1996 in Science, Allison went looking for a pharmaceutical company to develop a CTLA-4 inhibitor for humans. He ran into a wall. Since the demise of Coley’s Toxin, several types of immunotherapy had showed promise in animal models, only to fail in people. The few that worked either had narrow applications or marginal success rates.

For two years, Allison got nothing but rejections, but his old stubbornness kept him going. At last, a small New Jersey-based company called Medarex said yes. Its scientists began working with Allison to develop the new medication. And by 2001, ipilimumab was ready for testing....

http://discovermagazine.com/2016/nov/checkmate

I will be very curious if Dr Allison OR Dr Sharma would break from the pack and realize PS Targeting is required for any chance in giving the most patients the best chance in surviving